Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A Study of an Intermittent ADT Approach with Apalutamide Monotherapy in Participants with mCSPC Ended

2022-502686-24-00 Metastatic Castration-Sensitive Prostate Cancer (mCSPC) 5 2023-11-22
Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended

2023-505023-31-00 Renal cell carcinoma 5 2023-11-17
A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M… Ended

2022-501863-41-00 Subjects With Stage IV or Advanced Stage IIIB/C Nonsqua 5 2023-11-13
Phase Ib/II non-randomized non-comparative two-cohort study of Niraparib and Dostarlimab plus (Chemo)RadIotherapy in Locally-Advanced head a… Ended

2024-516779-33-00 Carcinoma 9 2023-11-08
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects wit… Ended

2022-500849-24-00 Advanced Solid Tumors 1 2023-11-07
Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy. DIAMOND STUDY Ended

2024-518017-26-00 metastatic HER2-positive breast cancer patients 4 2023-11-07
SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with metastatic hormone sensitive prostate cancer (mH… Ended

2023-507672-52-00 PSMA-positive metastatic hormone sensitive prostate can 7 2023-11-07
A phase 1/2 study of SLN124 in patients with Polycythemia Vera Ended

2023-503544-13-00 Polycythemia Vera 9 2023-11-02
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N… Ended

2022-500802-16-00 Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non- 5 2023-11-01
An open label, multicenter, phase II study of Elranatamab as single agent for the treatment of relapsed or refractory myeloma in patients pr… Ended

2023-504273-21-00 Multiple Myeloma 4 2023-10-31
Phase I, double-blind, randomized, placebo-controlled study investigating the safety, tolerability and concentrations of the study product K… Ended

2023-503909-11-01 Ovarian cancer 1 2023-10-30
A Study to Evaluate Atezolizumab and Bevacizumab, with and without Tiragolumab, In Patients With Untreated Locally Advanced or Metastatic He… Ended

2023-503422-39-00 Hepatocellular Carcinoma (HCC) 5 2023-10-20
TIRACAN; Open label phase 2 basket trial with Atezolizumab and Tiragolumab in solid tumors Ended

2024-512616-21-00 HNSCC, metastatic deficient mismatch repair (dMMR)/MSI- 4 2023-10-18
A Study to Evaluate the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician’s Choice of Endocrine Therapy Plus E… Ended

2023-506821-12-00 Estrogen Receptor (ER)-Positive, HER2-Negative, Locally 5 2023-10-12
Sentinel node detection with 99Tc albumin nanocolloid and indocianine green (ICG) in patients with epithelial ovarian cancer in early stages… Ended

2023-505667-37-00 Epithelial ovarian cancer in early stages. 4 2023-10-06
SIERRA: Durvalumab and Tremelimumab as First Line Treatment in Participants with Advanced Hepatocellular Carcinoma Ended

2022-502012-37-00 Advanced Hepatocellular Carcinoma 5 2023-10-06
Phase 3 Study of V940 and Pembrolizumab in Resected Melanoma Ended

2023-503652-27-00 Melanoma 5 2023-10-06
Phase 3, Randomized, Open-Label Study of ARV-471 (PF-07850327) Plus Palbociclib vs Letrozole Plus Palbociclib in Participants With ER(+)/HER… Ended

2022-500545-24-00 ER + /HER 2 - Advanced Breast Cancer 5 2023-10-04
Effect of study drug combined with chemotherapy in patients with locally advanced or metastatic lung cancer with mutated receptor responsibl… Ended

2023-504434-22-00 Patients With EGFR-mutant Locally Advanced or Metastati 5 2023-10-03
Safety and efficacy analysis of an antibody associated with a chemotherapy for patients with a triple negative metastatic breast cancer. Ended

2022-502369-10-00 Triple negative metastatic breast cancer 5 2023-10-02
ELVN-002 in Solid Tumors with a HER2 Genetic Alteration Ended

2022-502695-23-00 Phase 1a Monotherapy Dose Escalation and Exploration: 1 2023-09-27
This is a phase 2 open label clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with… Ended

2024-512138-13-00 Recurrent ovarian cancer positive for MAGE-A4 in human 4 2023-09-27
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance T… Ended

2022-501346-30-00 Newly Diagnosed Multiple Myeloma with Suboptimal Respon 5 2023-09-25
A Study to Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination with Polatuzumab Vedotin Plus Rituximab, Cyclophospha… Ended

2023-504028-24-00 Large B-Cell Lymphoma 5 2023-09-22